Embodiments of the invention provide body armor composite and methods of fabrication. The body armor composite can include at least one strike-face layer, at least one strike-face reinforcement layer, and at least one catchment layer. Some embodiments include body armor composite with a bump guard layer, and a back-face reduction layer. In some embodiments, the fabrication method includes bonding multiple layers to form an armor composite. Some embodiments include an armor production tool including a housing at least two housing portions which form a substantially air-tight chamber when closed. The tool can include a lower flexible membrane forming at least a portion of a mold, and an upper flexible membrane capable of engaging the lower flexible membrane. The tool can include a pressure port for pressurizing the chamber and to move portions of the mold towards each other, and a locking mechanism for locking the two housing portions.

There is provided a method for producing a birefringent lens for a stereoscopic image display using a birefringent material having two or more liquid crystal compounds each having at least one polymerizable functional group. The method includes the steps of providing the birefringent lens material; applying the birefringent lens material onto an alignment layer that has been subjected to an alignment treatment in a uniaxial direction, and forming the coating film into a lens shape by conducting curing with ultraviolet light.

A photocurable composition for stereolithographic three-dimensional printing, wherein the photocurable composition comprises a photoreactive oligomer component comprising a hydrophobic oligomer comprising a photoreactive end group, a photoreactive monomer component comprising a photoreactive monomer having a photoreactive end group, and a photoinitiation composition comprising a photoinitiator; the photocurable composition has a viscosity of 250 to 10,000 centipoise at 22 C., determined using a Brookfield viscometer; and the photocured composition has a dielectric loss of less than 0.010, preferably less than 0.008, more preferably less than 0.006, most preferably less than 0.004, each determined by split-post dielectric resonator testing at 10 gigahertz at 23 C.

Provided are an electron beam curable resin composition including polymethylpentene, and a crosslinking agent, in which the crosslinking agent has a saturated or unsaturated ring structure, at least one atom among atoms forming at least one ring is bonded to any allylic substituent of an allyl group, a methallyl group, an allyl group through a linking group, and a methallyl group through a linking group, and a molecular weight is 1,000 or less, a resin frame for reflectors using the resin composition, a reflector, and a molding method using the resin composition.

A maleimide-based copolymer containing: 40% to 65% by mass of an aromatic vinyl-based monomer unit; and 35% to 60% by mass of a maleimide-based monomer unit, in which a residual amount of an aromatic vinyl-based monomer is 200 to 2000 ppm by mass, and a residual amount of a maleimide-based monomer is 30 to 400 ppm by mass.

A secure element has a card-type body made of a plurality of layers, arranged one above the other and generated by coextrusion. The secure element includes a first layer as the base layer made of a first material having a base polymer, wherein a first color is homogenously distributed in the first layer as the main color of the body. The secure element includes at least one second layer, as the colored layer made of a second material that has a carrier polymer. The base polymer and the carrier polymer have different material properties with randomized polychromatism visible in plan view and in cross section. The at least one second layer forms, together with the first layer in the card body in a random distribution, colored surface regions, which are dominated in part by the color of the first layer and in part by the color of the second layer.

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.